Valuation: LivaNova PLC

Market Cap 4.3B 3.75B 3.54B 3.21B 6.02B 412B 6.05B 42.39B 16.36B 210B 16.14B 15.79B 675B P/E 2026 *
19.5x
P/E 2027 * 23.5x
Enterprise Value 4.37B 3.81B 3.6B 3.27B 6.13B 420B 6.15B 43.13B 16.64B 213B 16.43B 16.06B 686B EV / Sales 2026 *
2.87x
EV / Sales 2027 * 2.58x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
Current month-1.46%
1 month-1.46%
3 months-1.46%
6 months+23.85%
Current year+28.57%
1 week 65.5
Extreme 65.5
69.5
1 month 65.5
Extreme 65.5
71.5
3 years 29.4
Extreme 29.4
74.5
5 years 29.4
Extreme 29.4
79.5
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+46.74%+26.17% 4.3B
+0.37%+0.65%-24.57%+1.93% 178B
-0.69%+1.29%-3.10%+11.50% 118B
-0.20%-3.98%+6.47%+71.79% 58.92B
-0.24%+1.74%-3.26%-31.97% 49.29B
-0.22%-0.37%+10.27%+40.45% 48.17B
+1.61%+7.61%+32.47%-5.11% 33.72B
-1.49%-2.74% - - 27.76B
-1.17%+4.64%+42.17%-7.72% 25.5B
+1.02%+5.99%+6.51%-15.81% 22.1B
Average -0.11%+1.85%+12.63%+10.14% 62.32B
Weighted average by Cap. -0.08%+1.03%-2.79%+10.60%

Financials

2026 *2027 *
Net sales 1.52B 1.33B 1.25B 1.14B 2.13B 146B 2.14B 15.01B 5.79B 74.25B 5.72B 5.59B 239B 1.63B 1.42B 1.34B 1.22B 2.28B 156B 2.29B 16.08B 6.2B 79.53B 6.12B 5.99B 256B
Net income 226M 197M 186M 169M 317M 21.71B 318M 2.23B 861M 11.04B 850M 831M 35.51B 187M 163M 154M 140M 262M 17.94B 263M 1.84B 711M 9.12B 702M 687M 29.34B
Net Debt 75M 65.4M 61.75M 56.08M 105M 7.2B 106M 740M 285M 3.66B 282M 275M 11.77B -85M -74.12M -69.99M -63.55M -119M -8.16B -120M -838M -324M -4.15B -319M -312M -13.34B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Date Price Change
18/09/26 EUR 67.50 0.00%
17/09/26 EUR 67.50 -0.74%
16/09/26 EUR 68.00 -0.73%
15/09/26 EUR 68.50 +3.79%
14/09/26 EUR 66.00 -2.22%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
78.01USD
Average target price
89.10USD
Spread / Average Target
+14.22%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!